AdAlta is a clinical stage drug company using its proprietary i-body (single domain antibody) platform to discover and develop therapeutics for high unmet need diseases and drug targets that challenge traditional antibodies. Lead asset, AD-214 is in Phase I clinical trials and being developed for a range of fibrotic diseases and cancer. It has Orphan Drug Designation for Idiopathic Pulmonary Fibrosis. Our second asset is being developed in collaboration with GE Healthcare for molecular imaging in immuno-oncology. We aim to add a further collaboration and two more internal programs by the end of 2021.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):